| |
| |
|
| Insider
Information: |
Dupont Jakob |
| Relationship: |
|
| City: |
Redwood City |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
376,035 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$231,710 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
376,035 |
|
|
| Total
Value |
$231,710 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -110.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Gossamer Bio Inc |
GOSS |
Chief Medical Officer |
2020-02-14 |
46,500 |
2019-12-27 |
0 |
Premium* |
|
|
Atara Biotherapeutics, Inc. |
ATRA |
EVP, Head of R&D |
2023-03-02 |
290,794 |
2020-05-14 |
0 |
Premium* |
|
|
Pyxis Oncology, Inc. |
PYXS |
|
2024-03-26 |
38,741 |
2024-03-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PYXS |
Pyxis Oncology, Inc. |
|
– • – |
2024-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
38,741 |
38,741 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2023-03-02 |
4 |
AS |
$3.63 |
$18,403 |
D/D |
(5,074) |
290,794 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• • – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
141,328 |
295,868 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• • – |
2022-11-16 |
4 |
AS |
$4.49 |
$19,497 |
D/D |
(4,342) |
154,540 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• • – |
2022-08-16 |
4 |
AS |
$5.03 |
$20,760 |
D/D |
(4,124) |
158,882 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• • – |
2022-05-17 |
4 |
AS |
$5.32 |
$20,597 |
D/D |
(3,873) |
163,006 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
78,506 |
169,100 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• • – |
2022-03-01 |
4 |
AS |
$9.86 |
$21,890 |
D/D |
(2,221) |
166,879 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2022-02-10 |
4 |
AS |
$16.00 |
$80,000 |
D/D |
(5,000) |
90,594 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2022-02-10 |
4 |
OE |
$9.58 |
$47,900 |
D/D |
5,000 |
95,594 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2022-01-03 |
4 |
AS |
$16.01 |
$80,050 |
D/D |
(5,000) |
90,594 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2022-01-03 |
4 |
OE |
$9.58 |
$47,900 |
D/D |
5,000 |
95,594 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2021-12-01 |
4 |
AS |
$17.94 |
$89,689 |
D/D |
(5,000) |
90,594 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2021-12-01 |
4 |
OE |
$9.58 |
$47,900 |
D/D |
5,000 |
95,594 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2021-11-16 |
4 |
AS |
$17.12 |
$37,640 |
D/D |
(2,199) |
90,594 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2021-11-02 |
4 |
AS |
$16.41 |
$82,050 |
D/D |
(5,000) |
92,793 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2021-11-02 |
4 |
OE |
$9.58 |
$47,900 |
D/D |
5,000 |
97,793 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2021-08-17 |
4 |
AS |
$12.53 |
$26,969 |
D/D |
(2,152) |
92,793 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2021-05-18 |
4 |
AS |
$14.55 |
$75,427 |
D/D |
(5,184) |
94,945 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
53,879 |
100,129 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
EVP, Head of R&D |
• – – |
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
46,250 |
46,250 |
0 |
- |
|
| GOSS |
Gossamer Bio Inc |
Chief Medical Officer |
• – – |
2020-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
46,500 |
46,500 |
0 |
- |
|
| GOSS |
Gossamer Bio Inc |
Chief Medical Officer |
• – – |
2019-12-30 |
4 |
S |
$15.00 |
$600,004 |
D/D |
(40,000) |
0 |
0 |
% |
|
| GOSS |
Gossamer Bio Inc |
Chief Medical Officer |
• – – |
2019-12-30 |
4 |
OE |
$10.71 |
$428,400 |
D/D |
40,000 |
40,000 |
0 |
- |
|
| GOSS |
Gossamer Bio Inc |
Chief Medical Officer |
• – – |
2019-12-27 |
4 |
S |
$15.81 |
$31,534 |
D/D |
(1,994) |
0 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
